Churchill Capital Corp. XI Class A
NNASDAQ:CCXICapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Michael Stuart Klein
- Full Time Employees
- 2
- Sector
- Finance
- Industry
- Financial conglomerates
- Address
- 640 Fifth Avenue, 12th Floor New York NY United States 10019
- IPO Date
- Dec 17, 2025
- CIK
- 0002074973
- Website
- churchillcapital-11.com
- Similar Companies
- Business
- ChemoCentryx, Inc. is a biopharmaceutical company engaged in the discovery, development, and commercialization of orally administered small molecule therapeutics targeting inflammatory disorders, autoimmune diseases, and cancer. The company’s core products include TAVNEOS (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor approved for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis). TAVNEOS is also in late-stage clinical development for severe hidradenitis suppurativa, complement 3 glomerulopathy, and lupus nephritis. In addition to TAVNEOS, ChemoCentryx develops CCX559, an orally administered inhibitor targeting programmed death protein 1/programmed death-ligand 1 (PD-1/PD-L1) for cancer therapy, and CCX507, an orally administered inhibitor of chemokine receptor CCR9 for inflammatory bowel disease, which has completed Phase I clinical trials. The company also holds early-stage drug candidates targeting Th17-driven diseases and chemokine receptor CCR6 for other inflammatory and autoimmune conditions. Founded in 1997 and headquartered in San Carlos, California, ChemoCentryx operates as a subsidiary of Amgen Inc. following its acquisition in 2022. Recent major changes include the completion of the acquisition by Amgen in 2022, a transaction valued at approximately $4 billion that integrated ChemoCentryx into Amgen’s rare disease and inflammation franchises. Post-acquisition, ChemoCentryx expanded its development pipeline within Amgen’s infrastructure, accelerating clinical programs for TAVNEOS and other candidates. Regulatory milestones include TAVNEOS’ market approval in the U.S. for ANCA-associated vasculitis and its European Union approval as a treatment combined with rituximab or cyclophosphamide. The company’s strategic focus remains on orphan and rare diseases with high unmet medical needs, leveraging its expertise in chemokine and chemoattractant receptor pathways to innovate disease-modifying therapies that selectively block pathological immune system cascades without broad immunosuppression. ChemoCentryx targets the biopharmaceutical sectors of autoimmune, inflammatory, and oncology diseases, with a geographic focus primarily in the United States and parts of Europe. The company’s product portfolio emphasizes oral therapeutics designed to improve patient adherence and quality of life. With a commitment to advancing treatment paradigms in rare and orphan diseases, ChemoCentryx continues to pursue clinical development and commercialization initiatives across multiple high-impact disease areas under Amgen ownership. The company’s research and development pipeline broadens its reach into immune-oncology and chronic inflammatory diseases, addressing both common and rare conditions through precision targeting of chemoattractant receptors. This comprehensive strategy aligns with ChemoCentryx’s founding mission and recent operational expansion, positioning it as a key player in biopharmaceutical innovation under the Amgen umbrella. The company maintains its focus on advancing orally administered small molecules that provide selective immunomodulation, reflecting its scientific expertise and commitment to patient-centric drug development. The integration with Amgen supports leveraging additional resources and capabilities to accelerate new drug approvals and market access globally.
Company News
Agility Robotics: Market Jitters Presenting A Golden Opportunity
The SPAC Sponsor Behind Lucid and Oklo Is Taking Agility Robotics Public on Nov. 5. Here's What Those 2 Stocks Did in Their First 90 Days.
Churchill Capital Corp XI Shareholders Approve Business Combination with Agility Robotics
Churchill Stock Explodes: What's Going On?
Agility Robotics and Churchill Capital Corp XI Announce Expected Gross Capital Raise of Approximately $465 Million and Anticipated Closing of Business Combination
Agility Robotics Highlights Commercial Momentum and Growing Enterprise Demand for Digit Humanoid Robot
GXO and Agility Robotics Expand Partnership to Accelerate Deployment of Humanoids in U.S. Operations
Agility Robotics Expands NVIDIA Collaboration as It Prepares Digit 5 for Commercial Scale
Agility Robotics Expands Pittsburgh Presence to Support Growing Customer Deployments
Churchill Capital: A Call Option On Agility, America's Nascent Humanoid Robotic Innovator
Agility Robotics Announces Audit Committee Chair for Planned Public-Company Board
Agility Robotics Selects Nyobolt as its Ultra-Fast Charging Battery Technology Partner for Digit 5
Unusual Options Volume Report: STLA, CCXI, GLND
Agility Robotics and Churchill Capital Corp XI S-4 Registration Statement Declared Effective by SEC in Connection with Proposed Business Combination
Agility Robotics Announces New Directors for Planned Public-Company Board
Agility Unveils Digit 5 Humanoid Robot Built for Cooperatively Safe Work at Scale
Agility Robotics to Attend Upcoming Investor Conferences
Why CCXI Stock Is Climbing Wednesday Following Unitree's Blockbuster IPO
Agility Robotics Strengthens Executive Leadership Team with Appointment of Michael Beer as Chief Financial Officer
Agility Opens New Fremont Facility to Accelerate Physical AI Development